<DOC>
	<DOCNO>NCT00371033</DOCNO>
	<brief_summary>The purpose study determine whether pregabalin effective treatment Chronic Prostatitis/Chronic Pelvic Pain Syndrome .</brief_summary>
	<brief_title>Efficacy &amp; Safety Study Pregabalin Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome ( CP/CPPS )</brief_title>
	<detailed_description>Primary Objectives 1 . To compare six ( 6 ) week treatment pregabalin versus placebo CP/CPPS participant respect primary endpoint NIH-CPSI 2 . To evaluate safety tolerability six ( 6 ) week pregabalin CP/CPPS participant Design Eligible participant receive either pregabalin placebo , randomly assign ratio 2:1 . Study treatment 6 week dose start 150mg go 300mg finally 600mg daily , maximum tolerate dose . Participants advise take study medication 3 time per day . There 3 clinic visit 2 telephone contact . Participants offer optional active treatment additional 6 week end first 6 week . For participate phase total 4 clinic visit 5 telephone contact .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Participant sign dated appropriate Informed Consent document . Participant must symptoms discomfort pain pelvic region least three ( 3 ) month period within last six ( 6 ) month . Participant continue evidence facultative Gram negative enterococcus value ≥ 1000 ≤ 100,000 CFU/ml midstream urine ( VB2 ) , demonstrate repeat culture obtain less seven ( 7 ) day post antibiotic treatment . Participant calculate creatinine clearance &lt; 60 mL/min . Participant platelet count &lt; 100,000/mm3 . Participant allergic antiepileptic/antiseizure medication . Participant know allergy sensitivity pregabalin ( Lyrica® ) . Participant take thiazolidinedione antidiabetic agent ( i.e . rosiglitazone pioglitazone ) . Participant New York Heart Association Class III IV congestive heart failure . Participant history thrombocytopenia , bleed diathesis . Participant history prostate , bladder urethral cancer . Participant history alcohol abuse . Participant inflammatory bowel disease ( Crohn 's disease ulcerative colitis , irritable bowel syndrome ) . Participant undergone pelvic radiation systemic chemotherapy . Participant undergone intravesical chemotherapy . Participant treat intravesical BCG . Participant unilateral orchalgia without pelvic symptom . Participant active urethral stricture . Participant neurological disease disorder affect bladder . Participant neurological impairment psychiatric disorder prevent understanding consent ability comply protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>